文献速递肝病

基于Fibrosis-4与肝硬度检测的照护模式对2型糖尿病晚期肝病风险患者筛查的有效性:意大利前瞻性多中心研究结果

Effectiveness of a Model of Care Based on Fibrosis-4 and Liver Stiffness Measurement for the Screening of Patients With Type 2 Diabetes Mellitus at Risk of Advanced Liver Disease: Results From an Italian Prospective Multicenter Study.
PubMed 文献 · Am J Gastroenterol · 2025-04-14

该意大利前瞻性多中心研究纳入6家糖尿病门诊连续800例2型糖尿病患者,评估代谢功能障碍相关脂肪性肝病患病率及FIB-4联合振动控制瞬时弹性成像两级筛查效果。肝脂肪变患病率73.6%,LSM≥8.0 kPa者16.9%,高危MASH者12.0%;两级筛查转诊肝科70例(8.8%),假阴性率9.6%。作者认为该模式可有效识别需转诊肝病医生的患者。

要点

  • 2型糖尿病患者中肝脂肪变(CAP≥248 dB/m)患病率为73.6%。
  • LSM≥8.0 kPa者占16.9%,FibroScan-AST>0.67的「高危MASH」者占12.0%。
  • FIB-4联合VCTE两级筛查转诊肝科70例(8.8%),假阴性率9.6%。

核心结论

  • 在糖尿病门诊,采用FIB-4和VCTE的两级筛查可有效识别需转诊肝病医生的2型糖尿病患者。
  • 作者认为,对FIB-4评估为晚期肝纤维化低风险但超重/肥胖且丙氨酸氨基转移酶升高的患者,可考虑转诊进行VCTE检查。

研究设计与样本

  • 意大利6家糖尿病门诊连续纳入的2型糖尿病患者前瞻性研究,共800例符合纳入标准。
  • 肝硬度采用振动控制瞬时弹性成像(VCTE)测量,肝脂肪变采用受控衰减参数评估。

主要发现

  • 800例患者中位年龄59岁(53-65岁),男性485例(60.6%)。
  • 肝脂肪变(CAP≥248 dB/m)患病率73.6%,晚期肝纤维化中/高风险(LSM≥8.0 kPa)比例16.9%。
  • 「高危MASH」(FibroScan-AST>0.67)者占12.0%。
  • FIB-4联合VCTE两级筛查转诊肝科70例(8.8%),假阴性率9.6%(n=77;FIB-4<1.3且LSM≥8.0 kPa的患者)。
  • 在FIB-4<1.3的患者中,多因素分析显示超重/肥胖(OR=3.13,95%CI 1.23-7.97)和丙氨酸氨基转移酶升高(OR=1.91,95%CI 1.17-3.10)与LSM≥8.0 kPa独立相关。

临床怎么用

  • 在糖尿病门诊,采用FIB-4和VCTE的两级筛查可有效识别需转诊肝病医生的2型糖尿病患者。
  • 作者认为,对FIB-4评估为晚期肝纤维化低风险但超重/肥胖且丙氨酸氨基转移酶升高的患者,可考虑转诊进行VCTE检查。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patients with type 2 diabetes mellitus (T2DM) are at increased risk of metabolic dysfunction-associated steatotic liver disease, advanced liver fibrosis, and metabolic dysfunction-associated steatohepatitis (MASH). We evaluated the prevalence and severity of metabolic dysfunction-associated steatotic liver disease among patients with T2DM at their first referral to diabetes clinics and assessed the effectiveness of the 2-tier screening approach by Fibrosis-4 (FIB-4) and vibration-controlled transient elastography (VCTE). METHODS: Consecutive patients with T2DM from 6 different diabetes clinics were prospectively enrolled. Liver stiffness measurement (LSM) was assessed by VCTE, whereas liver steatosis by controlled attenuation parameter (Fibroscan, Echosens, France). "At-risk MASH" was assessed by FibroScan-aspartate aminotransferase score. RESULTS: Eight hundred patients (median age: 59, 53-65 years; males: 485, 60.6%) met the inclusion criteria. Prevalence of liver steatosis (controlled attenuation parameter ≥ 248 db/m) was 73.6%. The proportion of patients at medium/high risk of advanced liver fibrosis (LSM ≥ 8.0 kPa) was 16.9%. Patients with "at-risk MASH" (FibroScan-aspartate aminotransferase > 0.67) were 12.0%. A 2-tier screening for advanced liver fibrosis by FIB-4 and VCTE would have led to 70 patients (8.8%) referred to liver clinics with a false-negative rate of 9.6% (n = 77; patients with FIB-4 < 1.3 and LSM ≥ 8.0 kPa). At multivariate analysis, overweight/obesity (odds ratio = 3.13, 95% confidence interval 1.23-7.97) and elevated alanine aminotransferase (odds ratio = 1.91, 95% confidence interval 1.17-3.10) were independently associated with LSM ≥ 8.0 kPa in patients with FIB-4 < 1.3. DISCUSSION: In diabetes clinics, the 2-tier screening using FIB-4 and VCTE is effective for the identification of patients with T2DM to be referred to hepatologists. VCTE referral may be considered for patients with overweight/obesity and elevated alanine aminotransferase classified as at low risk of advanced liver fibrosis by FIB-4.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Caviglia GP, Ferro A, D'Ambrosio R, et al. Effectiveness of a Model of Care Based on Fibrosis-4 and Liver Stiffness Measurement for the Screening of Patients With Type 2 Diabetes Mellitus at Risk of Advanced Liver Disease: Results From an Italian Prospective Multicenter Study. Am J Gastroenterol. 2025. PMID: 40226934. doi:10.14309/ajg.0000000000003493

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。